2020
DOI: 10.1017/s0033291720004316
|View full text |Cite
|
Sign up to set email alerts
|

Group transdiagnostic cognitive-behavior therapy for anxiety disorders: a pragmatic randomized clinical trial

Abstract: Background Transdiagnostic group cognitive-behavioral therapy (tCBT) is a delivery model that could help overcome barriers to large-scale implementation of evidence-based psychotherapy for anxiety disorders. The aim of this study was to assess the effectiveness of combining group tCBT with treatment-as-usual (TAU), compared to TAU, for the treatment of anxiety disorders in community-based mental health care. Methods In a multicenter single-blind, two-arm pragmatic superiority randomized … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
26
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6

Relationship

1
5

Authors

Journals

citations
Cited by 24 publications
(27 citation statements)
references
References 60 publications
1
26
0
Order By: Relevance
“…To facilitate this process, treatment developers can ensure that front-line clinicians are involved in developing and evaluating treatment protocols [ 43 46 ]. When treatment efficacy is known, researchers can contribute further by conducting "effectiveness" [ 47 50 ] or "pragmatic" [ 51 ] studies, with treatment providers, resources, and patients representative of "real-world" contexts [ 11 , 43 , 52 54 ]. As an illustration of this approach, some authors invite researchers to be mindful of trials’ exclusion criteria that would lead clinicians to have reasonable doubts about the applicability of the results to their clientele [ 44 , 55 59 ].…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…To facilitate this process, treatment developers can ensure that front-line clinicians are involved in developing and evaluating treatment protocols [ 43 46 ]. When treatment efficacy is known, researchers can contribute further by conducting "effectiveness" [ 47 50 ] or "pragmatic" [ 51 ] studies, with treatment providers, resources, and patients representative of "real-world" contexts [ 11 , 43 , 52 54 ]. As an illustration of this approach, some authors invite researchers to be mindful of trials’ exclusion criteria that would lead clinicians to have reasonable doubts about the applicability of the results to their clientele [ 44 , 55 59 ].…”
Section: Resultsmentioning
confidence: 99%
“…Because of resource discrepancies, interventions trialed exclusively during experiments [ 44 , 57 , 60 , 61 ] or in the context of a specialized clinic [ 48 , 55 , 62 , 63 ] may need to be tested for transferability to build a case for dissemination. Providing a more detailed account of crucial information, such as the specific training and supervision procedures employed [ 51 , 64 ], can facilitate replication. Detailed reporting can also enable translation or cultural adaptation of interventions to other contexts to circumvent the need to repeat the whole treatment development process [ 62 , 65 ], but the effectiveness of the intervention or its adaptations still needs to be rigorously tested in different contexts [ 66 68 ].…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Other meta-analyses of pharmacotherapy for GAD have been useful in indicating that a number of classes of medication are useful for GAD [ 18 ], that anxiolytic effects persist beyond the active treatment period [ 19 ], that maintenance treatment is effective in preventing relapse [ 20 ], and that effective treatment improves quality of life [ 21 ]. Much research is needed in this area, including trials of more representative patients [ 22 ], including those with significant comorbidity [ 23 ], trials of GAD across the patients’ lifespan [ 24 , 25 ], pragmatic trials [ 26 ], and trials of drugs that target novel mechanisms of action [ 14 ]. Future research may also include work based on translational neuroscience [ 27 ], epidemiological studies [ 28 ] and big data [ 29 ], and should also address the question of whether clinical characterization may improve personalized treatment [ 30 ].…”
Section: Evidence To Support Pharmacotherapy In Gadmentioning
confidence: 99%